Cross-Cutting Network Issues
FAQs for IMPAACT/HPTN Meeting - New CTU Awards
Microsoft Word
IMPAACT Community Advisory Board
Regional CAB Meeting Presentation
PowerPoint
Complications Scientific Committee Meeting
Capsule Update: CAP 182C: “Longitudinal Assessment of Bone Mineral Density in HIV-Infected Children
and Adolescents and Impact of Oral Alendronate Therapy Compared to Usual Nutritional Advice.”
– Bret Rudy, M.D., George Siberry, M.D., M.P.H.
PowerPoint
P1046: "A Phase I/II Trial of Stressgen SGN 00101, A Fusion Protein of the Mycobacterium Bovis Heat
Shock Protein 65 and the HPV 16 E7 Protein for the Treatment of Low Grade Squamous Intra-Epithelial
Lesions." - Myron Levin, M.D.
PowerPoint
P1065: “A Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate
Vaccine in HIV-Infected Youth.” – George Siberry, M.D.
PowerPoint
Long-term Follow-up Subcommittee Update - Myron Levin, M.D.
PowerPoint
TB Update - Lessons Learned from CROI - Raziya Bobat, M.D.
PowerPoint
International Presentations
Brazil - Maria Letícia Cruz, M.D.
PowerPoint
India - Amita Gupta, M.D., M.H.S.
PowerPoint
Malawi - Taha Taha, Ph.D.
PowerPoint
Botswana - Anchilla Mary Owor, MBChB
PowerPoint
IMPAACT Laboratory Plenary
Nevirapine Resistant HIV-1 Among Mozambican Infants in Utero vs. Early Postpartum - Lisa Frenkel, M.D.
PowerPoint
Blockade of T-Cell Co-inhibitory Signaling in HIV Disease: Implications for the Design of in Vitro Correlates
of Antigen-specific Immune Function - Donald Campbell, Ph.D., Steven Douglas, M.D.
PowerPoint
Pharmacologic Determination of ARV Exposure in Infants - Breast feeding and other Considerations
- Edmund Capparelli, Pharm.D.
PowerPoint
Laboratory Committee Meeting
Development of a Multiplex PCR Assay for Detection of P. Falciparum, P. Vivax, P. Ovale and P. Malariae
- Karen Carroll, M.D.
PowerPoint
Analysis of CD4/CD8 Ratios for the Early Diagnosis of HIV Infection in Infants -
Savita Pahwa, M.D. PowerPoint
Primary Therapy Scientific Committee Meeting
Protocols and/or Novel Agents in the Pipeline
a) P1066: A Multicenter, Open-Label, Noncomparative Study of the International Maternal Pediatric Adolescent
AIDS Clinical Trials Group to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK0518
in HIV-1 Infected Children – Sharon Nachman, M.D.
PowerPoint
b) CAP 200: Phase I/II Open-Label Pharmacokinetic Safety, Tolerability and Antiviral Activity of Vicriviroc
(SCH-417690), a Novel CCR5 Antagonist in combination regimens in Antiretroviral Therapy Experienced Children
and Adolescents – Rolando Viani, M.D.
PowerPoint
c) CAP 201: Pharmacokinetics of Efavirenz in HIV-infected Infants < 36 Months of Age with and without HIV/TB
Co-infection. – Edmund Capparelli, Pharm.D.
PowerPoint
Reports on Data from Ongoing and Recently Completed Studies
a) P1058: Intensive Pharmacokinetic Studies of Antiretroviral Drug Combination in Children
– Jennifer King, Pharm.D.
PowerPoint
b) P1038: A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir with or without
Saquinavir In HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors
– Edmund Capparelli, Pharm.D.
PowerPoint
c) P1020A: A Phase I/II Open Label Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632) in
Combination Regimens in ART Naïve and Experienced HIV-infected Infants, Children and Adolescents
– Richard Rutstein, M.D.
PowerPoint
d) P1030: Phase I/II Study of Lopinavir/Ritonavir in HIV-infected Infants < 6 months of age – Jorge Pinto, M.D.
PowerPoint
e) P1056: A Phase I/II Open Label Pharmacokinetic and Safety Study Of the Fixed-Dose Combination (FDC) of Stavudine
(D4t), Lamivudine (3TC) and Nevirapine (NVP) as GPO-VIR® Pediatric Chewable Tablets Versus the Individual Liquid
Formulations in HIV-Infected Children ≥ 6 Months to < 13 Years of Age in Thailand. - Tim Cressey, Ph.D.
PowerPoint
Vaccine Scientific Committee Meeting
HPTN 027: A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1
Infected Women in Uganda - Laura Guay, M.D.
PowerPoint
P1067: Phase I/II Trial to Evaluate the Safety, Tolerability, Immunogenicity and Optimal Dosing of the Merck Ad5-HIV-1
gag/pol/nef Trivalent Vaccine in HIV-Exposed Newborns. - Betsy McFarland, M.D.
PowerPoint
CROI 2007: Presented abstract - P1006 - T Cell Phenotypes And Responses to Vaccines in Severely Immunocompromised
HIV-Infected Children Initiating HAART in PACTG 1006 - Adriana Weinberg, M.D.
PowerPoint
Long Term Follow-Up Sub-Committee Meeting
PACTG 219c Closure Monitoring Updates - Paige Williams, Ph.D.
PowerPoint
Information to Collect for IMPAACT LTFU
PowerPoint
International Resource Committee Meeting
IMPAACT Long-term Follow-up Subcommittee Presentation - Myron Levin, M.D.
PowerPoint
IMPAACT Collaborations with Existing International Datasets - such as LeIDEA and ANECCA - Lynne Mofenson, M.D., F.A.A.P.
PowerPoint
Process of Matching Protocols to Sites - Brooks Jackson, M.D.
PowerPoint
IMPAACT
Home
